


**In the Claims.** Applicants request amendment of the Claims prior to any action on the merits. The following listing of the claims shall replace all previous versions.

Claim 1. (Currently Amended) A Compound of the structural formula I:

Formula I



(a) R1 is hydrogen;

(b) R2' ~~is are each independently~~ selected from a group consisting of C<sub>1</sub>-C<sub>5</sub> alkyl, C<sub>3</sub>-C<sub>6</sub> cycloalkyl, C<sub>1</sub>-C<sub>5</sub> alkoxy, arylC<sub>0</sub>-C<sub>2</sub>alkoxy, haloC<sub>1</sub>-C<sub>3</sub>alkyl, halo, aryl, -C(O)C<sub>1</sub>-C<sub>5</sub>alkyl, -C(O)-aryl, haloC<sub>1</sub>-C<sub>5</sub>alkyloxy, arylC<sub>1</sub>-C<sub>5</sub>alkyl, and biarylC<sub>1</sub>-C<sub>5</sub>alkyl; and which -C(O)-aryl is unsubstituted or substituted with from one to three substituents each independently selected from the group consisting of halo, C<sub>1</sub>-C<sub>5</sub> alkyl, haloC<sub>1</sub>-C<sub>5</sub> alkyl, C<sub>1</sub>-C<sub>5</sub> alkoxy, and -C(O)C<sub>1</sub>-C<sub>5</sub>alkyl; and which C<sub>1</sub>-C<sub>5</sub> alkyl, arylC<sub>1</sub>-C<sub>5</sub>alkyl, biarylC<sub>1</sub>-C<sub>5</sub>alkyl, and aryl are each independently unsubstituted or substituted with from one to three substituents each independently selected from the group consisting of halo, C<sub>1</sub>-C<sub>8</sub>alkyl, aryl, haloC<sub>1</sub>-C<sub>5</sub> alkyl, trihaloC<sub>1</sub>-C<sub>3</sub>alkyl, C<sub>1</sub>-C<sub>5</sub>alkoxy, and arylC<sub>1</sub>-C<sub>5</sub>alkyl; and which aryl is unsubstituted or substituted with from one to three substituents each independently selected from the group consisting of halo, C<sub>1</sub>-C<sub>8</sub>alkyl, aryl, haloC<sub>1</sub>-C<sub>5</sub> alkyl, trihaloC<sub>1</sub>-C<sub>3</sub>alkyl, C<sub>1</sub>-C<sub>5</sub>alkoxy, and arylC<sub>1</sub>-C<sub>5</sub>alkyl;

(c) R2 is selected from the group consisting of C<sub>1</sub>-C<sub>8</sub> alkyl, C<sub>3</sub>-C<sub>6</sub> cycloalkyl, aryl-C<sub>0-4</sub>-alkyl, aminoC<sub>1</sub>-C<sub>4</sub>alkyl, C<sub>3</sub>-C<sub>6</sub> cycloalkylaryl-C<sub>0-2</sub>-alkyl, arylheteroC<sub>1</sub>-C<sub>8</sub>alkyl, C<sub>0-4</sub>-alkyl-C(O)heteroC<sub>1</sub>-C<sub>8</sub>alkyl, -CH(C(O)OCH<sub>3</sub>)benzyl, and -CH<sub>2</sub>-C(O)-R15''-R16'', and which C<sub>1</sub>-C<sub>8</sub> alkyl, C<sub>3</sub>-C<sub>6</sub> cycloalkyl, aryl-C<sub>0-4</sub>-alkyl, aminoC<sub>1</sub>-C<sub>4</sub>alkyl, C<sub>3</sub>-C<sub>6</sub> cycloalkylaryl-C<sub>0-2</sub>-alkyl, arylheteroC<sub>1</sub>-C<sub>8</sub>alkyl, C<sub>0-4</sub>-alkyl-

C(O)heteroC<sub>1</sub>-C<sub>8</sub>alkyl, and -CH<sub>2</sub>-C(O)-R15''-R16'' are each independently unsubstituted or substituted with from one to three substituents each independently selected from the group consisting of R2';

(d) R15'' is O or NH;

(e) R16'' is C<sub>1</sub>-C<sub>2</sub> alkyl or benzyl which C<sub>1</sub>-C<sub>2</sub> alkyl and benzyl are each unsubstituted or substituted with from one to three substituents each independently selected from the group consisting of R16';

(f) R7' and R7'' are each independently selected from the group consisting of C<sub>1</sub>-C<sub>4</sub> alkyl and C<sub>1</sub>-C<sub>4</sub> haloalkyl;

(g) n and m are each independently selected from the group consisting of 0, 1, 2 and 3;

(h) A is selected from the group consisting of (CH<sub>2</sub>)<sub>m</sub> COOR14, C<sub>1</sub>-C<sub>3</sub>alkylnitrile, carboxamide, sulfonamide, acylsulfonamide and tetrazole, and which sulfonamide, acylsulfonamide and tetrazole are each independently unsubstituted or substituted with from one to three substituents each independently selected from the group consisting of A';

(i) A' is a group consisting of C<sub>1</sub>-C<sub>4</sub>alkyl, C<sub>1</sub>-C<sub>4</sub> haloalkyl, heteroaryl, and aryl, and wherein heteroaryl and aryl are each independently unsubstituted or substituted with from one to three substituents each independently selected from the group consisting of halo, C<sub>1</sub>-C<sub>5</sub> alkyl, C<sub>1</sub>-C<sub>5</sub> haloalkyl, C<sub>1</sub>-C<sub>5</sub> alkoxy, and -C(O) C<sub>1</sub>-C<sub>5</sub> alkyl;

(j) R3 is selected from the group consisting of H, C<sub>1</sub>-C<sub>5</sub> alkyl, C<sub>1</sub>-C<sub>5</sub> alkenyl, and C<sub>1</sub>-C<sub>6</sub> alkoxy;

(k) R4 is selected from the group consisting of H, halo, C<sub>1</sub>-C<sub>5</sub> alkyl, C<sub>1</sub>-C<sub>6</sub> alkoxy, C<sub>3</sub>-C<sub>6</sub> cycloalkyl, aryl C<sub>0</sub>-C<sub>4</sub> alkyl, and C<sub>0-4</sub>alkoxyaryl, and which C<sub>1</sub>-C<sub>5</sub> alkyl, C<sub>1</sub>-C<sub>5</sub> alkoxy, C<sub>3</sub>-C<sub>6</sub> cycloalkyl, aryl C<sub>0</sub>-C<sub>4</sub> alkyl, and C<sub>0-4</sub>alkoxyaryl are each independently unsubstituted or each independently substituted with from one to four substituents each independently selected from R4'; or R3 and R4 are combined to form a C<sub>3</sub>-C<sub>6</sub> cycloalkyl;

(l) R5 and R6 are each independently selected from the group consisting of hydrogen, C<sub>1</sub>-C<sub>8</sub> alkyl, aryl-C<sub>0-4</sub>-alkyl, heteroaryl-C<sub>0-4</sub>-alkyl, C<sub>3</sub>-C<sub>6</sub> cycloalkylaryl-C<sub>0-</sub>

2-alkyl, C<sub>3</sub>-C<sub>6</sub> cycloalkyl-C<sub>0</sub>-2-alkyl, and -CH<sub>2</sub>-C(O)-R<sub>17</sub>-R<sub>18</sub>, and which C<sub>1</sub>-C<sub>8</sub> alkyl, aryl-C<sub>0</sub>-4-alkyl, heteroaryl-C<sub>0</sub>-4-alkyl, C<sub>3</sub>-C<sub>6</sub> cycloalkylaryl-C<sub>0</sub>-2-alkyl, C<sub>3</sub>-C<sub>6</sub> cycloalkyl-C<sub>0</sub>-2-alkyl, and -CH<sub>2</sub>-C(O)-R<sub>17</sub>-R<sub>18</sub> are each independently unsubstituted or substituted with from one to four substituents each independently selected from the group consisting of R<sub>5</sub>';

(m) R<sub>4</sub>', R<sub>5</sub>', and R<sub>13</sub>'' are each independently a group consisting of C<sub>1</sub>-C<sub>5</sub> alkyl, C<sub>1</sub>-C<sub>5</sub> alkoxy, C<sub>1</sub>-C<sub>5</sub> haloalkyl, C<sub>1</sub>-C<sub>5</sub> haloalkoxy, nitro, cyano, CHO, □hydroxyl, C<sub>1</sub>-C<sub>4</sub> alkanolic acid, phenyl, aryloxy, SO<sub>2</sub>R<sub>7</sub>', SR<sub>7</sub>'', arylC<sub>0</sub>-C<sub>2</sub>alkoxy, C<sub>1</sub>-C<sub>6</sub>alkylcarboxamido, and COOH;

(n) R<sub>16</sub>' is a group consisting of halo, C<sub>1</sub>-C<sub>8</sub>alkyl, aryl, haloalkyl, trihaloC<sub>1</sub>-C<sub>3</sub>alkyl, C<sub>1</sub>-C<sub>5</sub>alkoxy, and arylC<sub>1</sub>-C<sub>5</sub>alkyl;

(o) R<sub>17</sub> and R<sub>18</sub> are each independently selected from C<sub>1</sub>-C<sub>8</sub> alkyl, aryl-C<sub>0</sub>-4-alkyl, heteroaryl-C<sub>0</sub>-4-alkyl, C<sub>3</sub>-C<sub>6</sub> cycloalkylaryl-C<sub>0</sub>-2-alkyl, and C<sub>3</sub>-C<sub>6</sub> cycloalkyl-C<sub>0</sub>-2-alkyl;


(p) R<sub>14</sub> is selected from the group consisting of hydrogen, C<sub>1</sub>-C<sub>4</sub>alkyl, aryl, and arylmethyl, and which C<sub>1</sub>-C<sub>4</sub>alkyl are each independently unsubstituted or independently substituted with from one to three substituents each independently selected from the group consisting of R<sub>13</sub>' and which arylmethyl and aryl are each independently unsubstituted or independently substituted with from one to three substituents each independently selected from the group consisting of R<sub>14</sub>';

(q) R<sub>13</sub>' is a group consisting of C<sub>1</sub>-C<sub>5</sub> alkyl, C<sub>3</sub>-C<sub>6</sub> cycloalkyl, C<sub>1</sub>-C<sub>5</sub> haloalkyl, C<sub>1</sub>-C<sub>5</sub> alkoxy, aryloxy, halo, aryl, -C(O)C<sub>1</sub>-C<sub>5</sub>alkyl, -C(O)-aryl, haloC<sub>1</sub>-C<sub>5</sub>alkyloxy, aryl C<sub>1</sub>-C<sub>5</sub> alkyl, and C<sub>1</sub>-C<sub>5</sub> alkylbiaryl, and which -C(O)aryl, aryl, aryl C<sub>1</sub>-C<sub>5</sub> alkyl, and C<sub>1</sub>-C<sub>5</sub> alkylbiaryl are each independently unsubstituted or substituted with from one to three substituents each independently selected from the group consisting of R<sub>13</sub>''; and

(r) R<sub>14</sub>' is a group consisting of halo, C<sub>1</sub>-C<sub>8</sub>alkyl, C<sub>1</sub>-C<sub>5</sub> haloalkyl, C<sub>1</sub>-C<sub>5</sub> alkoxy, and arylC<sub>0</sub>-C<sub>4</sub>alkyl; or

(s) a pharmaceutically acceptable salt thereof.


2. (Original) A compound as claimed by Claim 1 of the structural Formula II:



II

wherein R19 is selected from the group consisting of hydrogen, C1-C4alkyl, aryl, and arylmethyl, wherein the alkyl, aryl and arylmethyl are each unsubstituted or substituted with from one to three substituents each independently selected from R14'.

3. (Previously presented) A compound as claimed by Claim 2 that is of the following structural formula III:



III

wherein R19 is selected from the group consisting of hydrogen, C1-C4alkyl, aryl, and arylmethyl, wherein the alkyl, aryl and arylmethyl are each unsubstituted or substituted with from one to three substituents each independently selected from R14'.

4. (Previously Presented) A compound as claimed by Claim 1 wherein R1 is hydrogen:-

5. (Previously Presented) A compound as claimed by Claim 4 wherein R2 is selected from the group consisting of arylC<sub>0</sub>-C<sub>4</sub>alkyl, C<sub>1</sub>-C<sub>8</sub> alkyl, heteroarylC<sub>0</sub>-C<sub>4</sub>alkyl, C<sub>3</sub>-C<sub>6</sub> cycloalkyl, C<sub>0</sub>-C<sub>4</sub>alkyl-C(O)-heteroC<sub>1</sub>-C<sub>8</sub> alkyl, arylheteroC<sub>1</sub>-C<sub>8</sub>alkyl, wherein each of said R2 is unsubstituted or substituted by one or two substituents each independently selected from the group consisting of phenyl, halophenyl, phenoxy, halo, haloC<sub>1</sub>-C<sub>4</sub> alkyl, C<sub>1</sub>-C<sub>4</sub>alkoxy, and C<sub>3</sub>-C<sub>6</sub> cycloalkyl.

6. (Original) A compound as claimed by Claim 5 wherein R2 is arylC<sub>0</sub>-C<sub>4</sub>alkyl wherein the aryl is phenyl or naphthyl, and the C<sub>0</sub>-C<sub>4</sub>alkyl is selected from the group consisting of methyl, ethyl and not present, that is C<sub>0</sub> alkyl.

7. (Withdrawn) A compound as claimed by Claim 5 wherein R2 is heteroarylC<sub>0</sub>-C<sub>4</sub>alkyl, and said heteroarylC<sub>0</sub>-C<sub>4</sub>alkyl is unsubstituted or substituted with from one to three substituents each independently selected from R2'; and wherein the heteroaryl is selected from the group consisting of pyridine, thiazole, benzothiazole, and thiadiazole; and the alkyl is selected from the group consisting of methyl, ethyl and not present, that is C<sub>0</sub> alkyl.


8. (Withdrawn) A compound as claimed by Claim 5 wherein R2 is arylheteroC<sub>1</sub>-C<sub>8</sub>alkyl, wherein the arylheteroC<sub>1</sub>-C<sub>8</sub>alkyl is unsubstituted or substituted with from one to three substituents each independently selected from the group consisting of R2'; wherein the aryl group is phenyl, and the heteroatom is selected from the group consisting of nitrogen, sulfur and oxygen.

9. (Previously Presented) A compound as claimed by of Claim 8 wherein the R2 group is substituted with one or two substituents each independently selected from the group consisting of methyl, ethyl, t-butyl, fluorine, chlorine, bromine, trifluoromethyl, methoxyl, ethoxyl, phenyl, and phenoxy.

10. (Canceled)

11. (Withdrawn) A compound as claimed by Claim 1, wherein said piperidine and piperazine is fused with a phenyl to form a bicyclic ring.

12. (Withdrawn) A compound as claimed by Claim 1, wherein R2 is unsubstituted or substituted heteroarylC<sub>0</sub>-C<sub>4</sub>alkyl; wherein said heteroaryl is selected from the group consisting of:



13. (Canceled).

14. (Previously Presented) A compound as claimed by Claim 1 wherein R2 is –CH(C(O)OCH<sub>3</sub>)benzyl.

15. (Previously Presented) A compound as claimed by Claim 1 or Claim 4 wherein R6 is selected from the group consisting of hydrogen, C<sub>1</sub>-C<sub>4</sub> alkyl, and aryl-C<sub>0</sub>-<sub>4</sub>-alkyl, wherein the alkyl and arylalkyl are each independently substituted with from one to three substituents each independently selected from the group consisting of R5'.

16. (Previously Presented) A compound as claimed by Claim 15 wherein R5 is H or methyl.

17. (Previously Presented) A compound as claimed by any one of Claims 1 or Claim 16 wherein R6 is C<sub>1</sub>-C<sub>3</sub> alkyl.


18. (Previously Presented) A compound as claimed by Claim 17, wherein R6 is methyl.

19. (Canceled)

20. (Previously Presented) A compound as claimed by Claim 1 wherein R5 is hydrogen or methyl, R6 is C<sub>1</sub>-C<sub>3</sub> alkyl, and R3 is C<sub>1</sub>-C<sub>3</sub>alkoxy.

21. (Previously Presented) A compound as claimed by Claim 1 wherein A is C(O)OR<sub>26</sub>; R<sub>26</sub> is H or C<sub>1</sub>-C<sub>3</sub>alkyl.


22. (Withdrawn) A compound as claimed by Claim 1 that is of the structural formula IV:



wherein R<sub>11</sub> is selected from the group consisting of aryl, -C(O)aryl, haloC<sub>1</sub>-C<sub>5</sub>alkyloxy, C<sub>1</sub>-C<sub>5</sub> alkylaryl, C<sub>1</sub>-C<sub>5</sub> alkylbiaryl, aryloxy, and C<sub>1</sub>-C<sub>6</sub> alkyl, wherein the aryl, -C(O)aryl, haloC<sub>1</sub>-C<sub>5</sub>alkyloxy, C<sub>1</sub>-C<sub>5</sub> alkylaryl, C<sub>1</sub>-C<sub>5</sub> alkylbiaryl, and C<sub>1</sub>-C<sub>6</sub> alkyl are each independently unsubstituted or each independently substituted with from one to three substituents each independently selected from the group consisting of R<sub>1</sub>'.

23. (Withdrawn) A compound as claimed by Claim 1 that is of the structural formula V:


V



wherein R12 is selected from the group consisting of aryl, aryloxy, -C(O)aryl, haloC<sub>1</sub>-C<sub>5</sub>alkyloxy, C<sub>1</sub>-C<sub>5</sub> alkylaryl, C<sub>1</sub>-C<sub>5</sub> alkylbiaryl, and C1-C6 alkyl, wherein the aryl, -C(O)aryl, haloC<sub>1</sub>-C<sub>5</sub>alkyloxy, C<sub>1</sub>-C<sub>5</sub> alkylaryl, C<sub>1</sub>-C<sub>5</sub> alkylbiaryl, and C1-C6 alkyl are each independently unsubstituted or each independently substituted with from one to three substituents each independently selected from the group consisting of R1'.

24. (Canceled)

25. (Withdrawn) A compound as claimed by Claim 1 that is of the structural formula VII:



VII

wherein wherein R12 is selected from the group consisting of aryl,aryloxy, -C(O)aryl, haloC<sub>1</sub>-C<sub>5</sub>alkyloxy, arylC<sub>1</sub>-C<sub>5</sub> alkyl, C<sub>1</sub>-C<sub>5</sub> alkylbiaryl, and C1-C6 alkyl, wherein the aryl, -C(O)aryl, aryloxy, haloC<sub>1</sub>-C<sub>5</sub>alkyloxy, C<sub>1</sub>-C<sub>5</sub> alkylaryl, C<sub>1</sub>-C<sub>5</sub> alkylbiaryl, and C1-C6



alkyl are each independently unsubstituted or each independently substituted with from one to three substituents each independently selected from the group consisting of R1'; R25 is selected from the group consisting of C1-C4alkyl, halo, haloC1-C3alkyl, C1-C5 alkoxy, and phenyl.

26. (Currently Amended) A compound as claimed by Claim 1 which is selected from the group consisting of:

(2S,1'R)-2-Ethoxy-3-(4-{1'-[2-(4-phenoxy-phenyl)-ethylcarbamoyl]-ethoxy}-phenyl)-propionic acid; (2S,1'R)-2-Ethoxy-3-(4-{1'-[2-(4-ethyl-phenyl)-ethylcarbamoyl]-ethoxy}-phenyl)-propionic acid; (2S,1'R)-2-ethoxy-3-(4-{1'-[2-(4-trifluoromethyl-phenyl)-ethylcarbamoyl]-ethoxy}-phenyl)-propionic acid;

(2S,1'R)-2-ethoxy-3-(4-{1'-[2-(2-ethoxy-phenyl)-ethylcarbamoyl]-ethoxy}-phenyl)-propionic acid;

(2S,1'R)-2-ethoxy-3-{4-[1'-(3-trifluoromethyl-benzylcarbamoyl)-ethoxy]-phenyl}-propionic acid;

(2S,1'R)-2-ethoxy-3-{4-[1'-(3-fluoro-5-trifluoromethyl-benzylcarbamoyl)-ethoxy]-phenyl}-propionic acid;

(2S,1'R)-3-(4-{1'-[(biphenyl-3-ylmethyl)-carbamoyl]-ethoxy}-phenyl)-2-ethoxy-propionic acid;

(2S,1'R)-3-(4-{1'-[2-(3-chloro-phenyl)-ethylcarbamoyl]-ethoxy}-phenyl)-2-ethoxy-propionic acid;

(2S,1'R)-2-ethoxy-3-(4-{1'-[2-(3-fluoro-phenyl)-ethylcarbamoyl]-ethoxy}-phenyl)-propionic acid;

(2S,1'R)-2-ethoxy-3-(4-{1'-[2-(2-fluoro-phenyl)-ethylcarbamoyl]-ethoxy}-phenyl)-propionic acid;

(2S,1'R)-3-(4-{1'-[2-(2,4-dichloro-phenyl)-ethylcarbamoyl]-ethoxy}-phenyl)-2-ethoxy-propionic acid;

(2S,1'R)-3-(4-{1'-[2-(2,6-dichloro-phenyl)-ethylcarbamoyl]-ethoxy}-phenyl)-2-ethoxy-propionic acid;

(2S,1'R)-3-(4-{1'-[2-(2-chloro-phenyl)-ethylcarbamoyl]-ethoxy}-phenyl)-2-ethoxy-propionic acid;(2S,1'R)-3-(4-{1'-[2-(4-tert-butyl-phenyl)-ethylcarbamoyl]-ethoxy}-phenyl)-2-ethoxy-propionic acid;

(2S,1'R)-2-ethoxy-3-{4-[1'-(4-fluoro-benzylcarbamoyl)-ethoxy]-phenyl}-propionic acid;(2S,1'R)-2-ethoxy-3-{4-[1'-(4-trifluoromethyl-benzylcarbamoyl)-ethoxy]-phenyl}-propionic acid;

(2S,1'R)-3-{4-[1'-(4-tert-butyl-benzylcarbamoyl)-ethoxy]-phenyl}-2-ethoxy-propionic acid;(2S,1'R)-3-{4-[1'-(4-tert-butyl-phenylcarbamoyl)-ethoxy]-phenyl}-2-ethoxy-propionic acid;(2S,1'R)-3-{4-[1'-(4-trans-tert-butyl-cyclohexylcarbamoyl)-ethoxy]-phenyl}-2-ethoxy-propionic acid;

(2S)-3-{4-[1-(4-tert-butyl-cyclohexylcarbamoyl)-1-methyl-ethoxy]-phenyl}-2-methoxy-propionic acid;

(2S)-2-methoxy-3-(4-{1-methyl-1-[2-(4-phenoxy-phenyl)-ethylcarbamoyl]-ethoxy}-phenyl)-propionic acid;

(2S)-3-(4-{1-[2-(2-ethoxy-phenyl)-ethylcarbamoyl]-1-methyl-ethoxy}-phenyl)-2-methoxy-propionic acid;

2-methoxy-3-(4-{1-methyl-1-[2-(3-trifluoromethyl-phenyl)-ethylcarbamoyl]-ethoxy}-phenyl)-propionic acid;

(2S)-2-methoxy-3-{4-[1-methyl-1-(3-trifluoromethyl-benzylcarbamoyl)-ethoxy]-phenyl}-propionic acid; (2S)-3-(4-{1-[2-(2-chloro-phenyl)-ethylcarbamoyl]-1-methyl-ethoxy}-phenyl)-2-methoxy-propionic acid;

(2S)-3-(4-{1-[(biphenyl-3-ylmethyl)-carbamoyl]-1-methyl-ethoxy}-phenyl)-2-methoxy-propionic acid;

(2S)-3-(4-{1-[2-(2,5-dimethoxy-phenyl)-ethylcarbamoyl]-1-methyl-ethoxy}-phenyl)-2-methoxy-propionic acid;

(2S)-3-(4-{1-[2-(2-fluoro-phenyl)-ethylcarbamoyl]-1-methyl-ethoxy}-phenyl)-2-methoxy-propionic acid;

(2S)-2-ethoxy-3-(4-{1-methyl-1-[2-(3-trifluoromethyl-phenyl)-ethylcarbamoyl]-ethoxy}-phenyl)-propionic acid;

(2S)-2-ethoxy-3-{4-[1-(3-fluoro-5-trifluoromethyl-benzylcarbamoyl)-1-methyl-ethoxy]-phenyl}-propionic acid;

(2S)-3-(4-{1-[2-(2-chloro-phenyl)-ethylcarbamoyl]-1-methyl-ethoxy}-phenyl)-2-ethoxy-propionic acid;(2S)-3-(4-{1-[(biphenyl-3-ylmethyl)-carbamoyl]-1-methyl-ethoxy}-phenyl)-2-ethoxy-propionic acid;

(2S)-3-(4-{1-[2-(3-chloro-phenyl)-ethylcarbamoyl]-1-methyl-ethoxy}-phenyl)-2-ethoxy-propionic acid;

(2S)-3-(4-{1-[2-(2,5-dimethoxy-phenyl)-ethylcarbamoyl]-1-methyl-ethoxy}-phenyl)-2-ethoxy-propionic acid;

(2S)-2-ethoxy-3-(4-{1-[2-(2-fluoro-phenyl)-ethylcarbamoyl]-1-methyl-ethoxy}-phenyl)-propionic acid;

(2S)-3-{3-[1-(4-tert-butyl-cyclohexylcarbamoyl)-1-methyl-ethoxy]-phenyl}-2-methoxy-propionic acid;

(2S)-3-{3-[1-(3-fluoro-5-trifluoromethyl-benzylcarbamoyl)-1-methyl-ethoxy]-phenyl}-2-methoxy-propionic acid;

(2S)-3-(3-{1-[(biphenyl-3-ylmethyl)-carbamoyl]-1-methyl-ethoxy}-phenyl)-2-methoxy-propionic acid;

(2S)-3-(3-{1-[2-(3-chloro-phenyl)-ethylcarbamoyl]-1-methyl-ethoxy}-phenyl)-2-methoxy-propionic acid;

(2S)-2-methoxy-3-{4-[(1-phenyl-ethylcarbamoyl)-methoxy]-phenyl}-propionic acid;

(2S)-3-(3-{1-[2-(2,4-dichloro-phenyl)-ethylcarbamoyl]-1-methyl-ethoxy}-phenyl)-2-methoxy-propionic acid;

(2S)-3-(3-{1-[2-(2,6-dichloro-phenyl)-ethylcarbamoyl]-1-methyl-ethoxy}-phenyl)-2-methoxy-propionic acid;

(2S)-3-(4-{1-[2-(2,4-dichloro-phenyl)-ethylcarbamoyl]-1-methyl-ethoxy}-phenyl)-2-methoxy-propionic acid;

(2S)-3-(4-{1-[2-(2,4-dichloro-phenyl)-ethylcarbamoyl]-1-methyl-ethoxy}-phenyl)-2-ethoxy-propionic acid;

(2S)-3-(4-{1-[2-(2,6-dichloro-phenyl)-ethylcarbamoyl]-1-methyl-ethoxy}-phenyl)-2-ethoxy-propionic acid;

(2S)-2-ethoxy-3-(4-{1-[2-(4-ethyl-phenyl)-ethylcarbamoyl]-1-methyl-ethoxy}-phenyl)-propionic acid;

(2S)-2-ethoxy-3-(4-{1-[2-(2-ethoxy-phenyl)-ethylcarbamoyl]-1-methyl-ethoxy}-phenyl)-propionic acid;

2-Ethoxy-3-{4-[1-(3-trifluoromethyl-benzylcarbamoyl)-ethoxy]-phenyl}-propionic acid;

2-Ethoxy-3-{4-[1-(5-fluoro-3-trifluoromethyl-benzylcarbamoyl)-ethoxy]-phenyl}-propionic acid;

2-Ethoxy-3-{4-[1-(3-phenyl-benzylcarbamoyl)-ethoxy]-phenyl}-propionic acid;

2-Ethoxy-3-{4-[1-(4-phenoxy-phenylethylcarbamoyl)-ethoxy]-phenyl}-propionic acid;

2-Ethoxy-3-{4-[1-(3-trifluoromethyl-phenylethylcarbamoyl)-ethoxy]-phenyl}-propionic acid;

3-(4-{1-[2-(2,6-Dichloro-phenyl)-ethylcarbamoyl]-ethoxy}-phenyl)-2-ethoxy-propionic acid;

2-Ethoxy-3-(4-{1-[2-(4-ethyl-phenyl)-ethylcarbamoyl]-ethoxy}-phenyl)-propionic acid;

2-Ethoxy-3-(4-{1-[2-(4-ethyl-phenyl)-ethylcarbamoyl]-ethoxy}-phenyl)-propionic acid;

3-(4-{Cyclohexyl-[2-(4-ethyl-phenyl)-ethylcarbamoyl]-methoxy}-phenyl)-2-ethoxy-propionic acid; and

2-Ethoxy-3-(4-{1-[2-(4-ethyl-phenyl)-ethylcarbamoyl]-2-phenyl-ethoxy}-phenyl)-propionic acid; ~~and~~


or pharmaceutically acceptable salts thereof.

27. (Previously Presented) A compound as claimed by Claim 1 wherein the compound is selected from the group consisting of

(2S,1'R)-3-{4-[1'-(4-tert-butyl-cyclohexylcarbamoyl)-ethoxy]-phenyl}-2-ethoxy-propionic acid; or

pharmaceutically acceptable salts thereof.

28. (Original) A compound as claimed by Claim 1 wherein the compound is



; or a pharmaceutically acceptable salt thereof.

29. (Canceled)

30. (Previously Presented) A pharmaceutical composition, comprising a pharmaceutically acceptable carrier and at least one compound as claimed by Claim 1 or a pharmaceutically acceptable salt thereof.

31. (Canceled)

32. (Previously Presented) A method of treating diabetes mellitus in a mammal, comprising the step of administering to the mammal a therapeutically effective amount of at least one compound of Claim 1 or a pharmaceutically acceptable salt thereof.

33. (Previously Presented) A method of preventing diabetes mellitus in a mammal, comprising the step of administering to the mammal an effective amount of at least one compound of Claim 1 or a pharmaceutically acceptable salt thereof.

34. (Previously Presented) A method of treating Syndrome X in a mammal, comprising the step of administering to the mammal a therapeutically effective amount of at least one compound of Claim 1 or a pharmaceutically acceptable salt thereof.

35. (Canceled)


36. (Previously Presented) A compound or pharmaceutically acceptable salt thereof according to Claim 1 for use as a medicine.

37. (Canceled)

38. (Canceled)


39. (Canceled)

40. (Previously Presented) A compound of the formula




; or a pharmaceutically acceptable salt thereof.

41. (Withdrawn) A Compound of the formula



Wherein R1 is selected from the group consisting of hydrogen, C<sub>1</sub>-C<sub>4</sub>alkyl and arylC<sub>0</sub>-C<sub>4</sub>alkyl; R2 is selected from the group consisting of arylC<sub>0</sub>-C<sub>4</sub>alkyl, and heteroarylC<sub>0</sub>-C<sub>4</sub>alkyl; or a pharmaceutical acceptable salt thereof.

42. (Previously Presented) A compound as claimed by Claim 1 that is of the formula:



or a pharmaceutically acceptable salt thereof.

43. (Previously Presented) A compound as claimed by any one of Claims 1, or 42 wherein the compound is a pharmaceutically acceptable salt.

44. (Previously Presented) A compound of Claim 1 that is (2S)-3-(4-{[2-(2,6-dichloro-benzylsulfanyl)-ethylcarbamoyl]-methoxy}-phenyl)-2-methoxy-propionic acid.

45. (Previously Presented) A pharmaceutical composition comprising a pharmaceutically acceptable carrier and at least one compound as claimed by Claim 42 or 44.